… ProQR Announces Successful Defense of a Key Axiomer® Patent … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Patent Office (EPO) by two separate strawmen against ProQR’s granted patent EP 3234134 B1 , which is related to …
… ProQR and Rett Syndrome Research Trust Join Forces with … variant that causes Rett syndrome Collaboration expands ProQR’s commitment to advance the development of therapies … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Therapeutics to Host Virtual Analyst and Investor Event … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Program and member of the Scientific Advisory Board at ProQR. Prof. Gideon Hirschfield, MA(Oxon) MB BChir (Cantab) …
… ProQR to Focus Exclusively on Axiomer RNA-editing Technology … & CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … liver and CNS, which we believe have strong alignment with ProQR’s oligonucleotide delivery approaches. ProQR’s …
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Mas
… ProQR Announces Annual General Meeting of Shareholders to be … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives … be made available in the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “Financials and …
… ProQR Announces Annual General Meeting of Shareholders to be … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … be made available in the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “Financials and …
… ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives … and strategy, her insights will be valuable in supporting ProQR’s next phase of growth.” Dr. Hinsch Gylvin is a …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St